N1-(4-溴苯甲基)-N2,N2-二甲基乙烷-1,2-二胺 | 99862-34-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N1-(4-溴苯甲基)-N2,N2-二甲基乙烷-1,2-二胺
• 英文名称: N'-(4-bromobenzyl)-N,N-dimethylethane-1,2-diamine
• 英文别名: N1-(4-bromobenzyl)-N2,N2-dimethylethane-1,2-diamine；N,N-Dimethyl-N'-<4-brom-benzyl>-ethylendiamin；N,N-Dimethyl-N'-(4-brom-benzyl)-ethylendiamin；[(4-Bromophenyl)methyl][2-(dimethylamino)ethyl]amine；N-[(4-bromophenyl)methyl]-N',N'-dimethylethane-1,2-diamine
• CAS: 99862-34-7
• 化学式: C₁₁H₁₇BrN₂
• mdl: MFCD07408130
• 分子量: 257.173
• InChiKey: LZFYBEIKDOCTHC-UHFFFAOYSA-N

物化性质

• 沸点：
  309.8±22.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N1-(4-溴苯甲基)-N2,N2-二甲基乙烷-1,2-二胺 在 四(三苯基膦)钯 、 sodium carbonate 、 三乙胺 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 生成 3-Cyclopentyl-N-(2-dimethylamino-ethyl)-N-(4'-formyl-biphenyl-4-ylmethyl)-propionamide
  参考文献：
  名称：

  Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry

  摘要：

  High-throughput screening of an array of biphenylmethylamines synthesised by high-throughput solid-phase chemistry resulted in the identification of compounds with high-affinity for the 5-ht(5A) receptor. The structure-activity relationship within this series and further array synthesis led to the identification of the biphenylmethylamine derivative 11, a potent and selective 5-ht(5A) receptor antagonist. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.024
• 作为产物：
  描述：

  对溴苯甲醛 、 N,N-二甲基乙二胺 生成 N1-(4-溴苯甲基)-N2,N2-二甲基乙烷-1,2-二胺
  参考文献：
  名称：

  369.合成NN -二烷基Ñ '-arylalkyl- ñ '-4-喹唑啉基（或6-甲基-4-嘧啶基或4-甲基-2-嘧啶基）潜在的药理学兴趣的乙二胺

  摘要：

  DOI：

  10.1039/jr9610001908

文献信息

• [EN] CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CXCR7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014191929A1

  公开（公告）日：2014-12-04

  The present invention relates to derivatives of formula (I) Formula (I) wherein (R1)n, R 2a, R 2b, R 3a, R 3b, R 4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物 公式（I）其中（R1）n，R 2a，R 2b，R 3a，R 3b，R 4，L1，L2，X，Y 和 Ar1 如描述中所述，其制备方法，其药学上可接受的盐，以及其作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是其作为CXCR7受体调节剂的用途。
• LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Wakiyama Yoshinari

  公开号：US20100210570A1

  公开（公告）日：2010-08-19

  An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R 1 represents N-optionally substituted C 1-6 alkyl-N-optionally substituted C 1-6 alkylamino-C 1-6 alkyl; R 2 represents a hydrogen atom or optionally substituted C 1-6 alkyl; R 3 represents optionally substituted C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供以下化合物(1)或其药理学上可接受的盐或溶剂，其中A代表芳基；R1代表N-可选取代的C1-6烷基-N-可选取代的C1-6烷基氨基-C1-6烷基；R2代表氢原子或可选取代的C1-6烷基；R3代表可选取代的C1-6烷基或C3-6环烷基-C1-4烷基；m为1至3；n为0；p为0至2。这些化合物是新颖的林可霉素衍生物，对最近在感染性疾病治疗中引起问题的耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物药物，有助于预防或治疗细菌感染性疾病。
• CXCR7 RECEPTOR MODULATORS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160107997A1

  公开（公告）日：2016-04-21

  The present invention relates to derivatives of formula (I) wherein (R 1 ) n , R 2a , R 2b , R 3a , R 3b , R 4 , L 1 , L 2 , X, Y and Ar 1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物，其中（R1）n，R2a，R2b，R3a，R3b，R4，L1，L2，X，Y和Ar1如描述中所述，其制备方法，其制备的药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，尤其是它们作为CXCR7受体调节剂的用途。
• LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：Meiji Seika Kaisha Ltd.

  公开号：EP2151447A1

  公开（公告）日：2010-02-10

  An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R1 represents N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目的是提供式（1）化合物或其药理学上可接受的盐或溶液，其中 A 代表芳基；R1 代表 N-任选取代的 C1-6 烷基-N-任选取代的 C1-6 烷基氨基-C1-6 烷基；R2 代表氢原子或任选取代的 C1-6 烷基；R3 代表任选取代的 C1-6 烷基或 C3-6 环烷基-C1-4 烷基；m 为 1 至 3；n 为 0；p 为 0 至 2。这些化合物是新型的林可霉素衍生物，在治疗传染性疾病方面对耐药性肺炎链球菌有很强的活性，而耐药性肺炎链球菌近来已造成了一些问题。此外，这些化合物还可用作抗菌剂，用于预防或治疗细菌性传染病。
• 369. Synthesis of NN-dialkyl-N′-arylalkyl-N′-4-quinazolyl(or 6-methyl-4-pyrimidyl or 4-methyl-2-pyrimidyl)ethylenediamines of potential pharmacological interest
  作者：N. B. Chapman、H. Taylor

  DOI：10.1039/jr9610001908

  日期：——